2025 Q2 -tulosraportti
229 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·5 min sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»
·34 min sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense
·46 min sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.
·4 min sittenYou who wrote that we would close at 12... where did you go,?
·58 min sittenIf nothing else, there will probably be another annual report tomorrow morning which will be pleasant reading - and perhaps useful for new ones who want a summary of why Circio is where it is today.
1 t sitten1 t sitten.·37 min sittenYes this is from 26 February! https://www.circio.com/en/wp-content/uploads/sites/2/2025/06/260226-1q26-webcast.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
229 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 min sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»
- ·34 min sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense
- ·46 min sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.·4 min sittenYou who wrote that we would close at 12... where did you go,?
- ·58 min sittenIf nothing else, there will probably be another annual report tomorrow morning which will be pleasant reading - and perhaps useful for new ones who want a summary of why Circio is where it is today.
- 1 t sitten1 t sitten.·37 min sittenYes this is from 26 February! https://www.circio.com/en/wp-content/uploads/sites/2/2025/06/260226-1q26-webcast.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
229 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. | 1 päivä |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·5 min sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»
- ·34 min sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense
- ·46 min sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.·4 min sittenYou who wrote that we would close at 12... where did you go,?
- ·58 min sittenIf nothing else, there will probably be another annual report tomorrow morning which will be pleasant reading - and perhaps useful for new ones who want a summary of why Circio is where it is today.
- 1 t sitten1 t sitten.·37 min sittenYes this is from 26 February! https://www.circio.com/en/wp-content/uploads/sites/2/2025/06/260226-1q26-webcast.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt